Fofiu C, Boeriu A, Coman F, Fofiu A, Panic N, Bulajic M, Dobru D

Idioma: Ingles.
Referencias bibliográficas: 31
Paginas: 137-143
Archivo PDF: 153.56 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Petruzziello A, Margliano S, Loquercio G, Cozzolino A, Cacciapioti C. Global epidemiology of hepatitis C virus infection: An up-date of the disstribution and circulation of hepatitis C virus genotypes. World J Gastroenterol 2016;22: 7824-40.

2. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35: 704-8.

3. Camma C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, Marcellin P, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39: 333-42.

4. Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, Pastore G, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004; 40: 675-81.

5. Hung CH, Lee CM, Lu SN, Wang JH, Hu TH, Tung HD, Chen CH, et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat 2006; 13: 409-14.

6. John Baptiste AA, Tomlinson G, Hsu PC, Krajden M, Heathcote EJ, Laporte A, Yoshida EM, et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol 2009; 104: 2439-48.

7. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with Peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139: 1593-601.

8. AASLD/IDSA HCV guidance panel hepatitis C Guidance: AASLD-IDSA recommendations for testing, managing and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932-54.

9. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63: 199-236.

10. Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, Elkhashab M, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/ paritaprevir/r and dasabuvir for 12 weeks. J Hepatol 2016; 64: 301-7.

11. Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, et al. Triple therapy in treatment-experienced patients with HCV cirrhosis in a multicenter cohort of the French Early Access Programme (ANRS CO20-CUPIC)- NCT01514890. J Hepatol 2013; 59: 434-41.

12. Colombo M, Fernandez I, Abdurakhmanov D, Ferreira PA, Strasser SI, Urbanek P, Moreno C, et al. Safety and ontreatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut 2013; 63: 1150-8.

13. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, et al. Boceprevir for untreated Chronic HCV genotype 1 infection. N Eng J Med 2011; 364: 1195-206.

14. Jacobson IM, McHutchison JG, Dusheiko G, Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. Telaprevir for pre viously untreated chronic hepatitis C virus infection. N Eng J Med 2011; 364: 2405-16.

15. Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, et al. Daclatasvir plus Asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59: 2083-91.

16. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, et al. Long term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875-81.

17. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, et al. ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with cirrhosis. N Eng J Med 2014; 370: 1973-82.

18. FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. 10/22/2015.

19. Zuckerman E, Ashkenasi E, Kovalev Y, Weitzman E, Tur- Kaspa R, Brown M, Cohen M, et al. The Real-World Israeli experience of treating chronic hepatitis C (CHC), genotype 1 (GT1) patients with advanced fibrosis with paritaprevir/ ritonavir/ombitasvir, dasabuvir with or without ribavirin (3D ± R): a large multi-center cohort. EASL 2016 Barcelona April 14-17.

20. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237-64.

21. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology 2002; 122: 1554-68.

22. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, Müllhaupt B, et al. ABT-450, Ritonavir, Ombitasvir, and Dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147: 359-65.

23. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Heckaman M, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368: 45-53.

24. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, et al. HCV RESPOND-2 final results: high sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir plus PegIntron (peginterferon alfa-2b)/ribavirin. Hepatology 2010; 52(Suppl. 430A). Abstract.

25. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.

26. Manns MP, Bourličre M, Benhamou Y, Pol S, Bonacini M, Trepo C, Wright D, et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011; 54: 1114-22.

27. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44.

28. Cavalcante LN, Lyra AC. Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol 2015; 7(12): 1617-31.

29. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourličre M, Sulkowski MS, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370(17): 1604-14.

30. Hasin Y, Shteingart S, Dahari H, Gafanovich I, Floru S, Braun M, Shlomai A, et al. Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: case report. World J Hepatol 2016; 8: 858-62.

31. Masetti M, Magalotti D, Martino E, Andreone P, Scuteri A, Zoli M. A Case of Acute Liver Failure during Ritonavir-Boosted Paritaprevir, Ombitasvir and Dasabuvir Therapy in a Patient with HCV Genotype 1b Cirrhosis. J Gastrointestin Liver Dis 2016; 25: 559-61.